From Hepatitis to Encephalitis: Neuroinvasion and Antiviral Development in Rift Valley Fever Virus Infection
Pathogens·
- DOI
- 10.3390/pathogens15090891
- PMID
- —
- PMCID
- —
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- MDPI AG
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The work highlights a critical gap in available medical countermeasures for a pathogen with significant agricultural and human health impacts. By outlining a comprehensive evaluation framework, the publication aims to guide the development of treatments that mitigate severe neurological sequelae.
Structured evidence summary
Research question
This review addresses the need for antiviral countermeasures against Rift Valley fever virus that effectively manage both acute systemic symptoms and subsequent central nervous system complications.
Study design
The authors conducted a narrative review evaluating existing literature on viral neuroinvasion mechanisms and current antiviral development strategies.
Population and setting
The analysis focuses on human and animal hosts infected with Rift Valley fever virus, specifically examining cases involving hepatic involvement and subsequent neurological or ocular manifestations.
Main findings
The authors summarize established pathways of viral entry into the central nervous system and evaluate various therapeutic approaches based on their pharmacological properties. They conclude that standard survival and viral-load metrics are insufficient, recommending that future clinical evaluations incorporate blood-brain barrier penetration and delayed-treatment efficacy to address neurological outcomes.
Public-health relevance
The work highlights a critical gap in available medical countermeasures for a pathogen with significant agricultural and human health impacts. By outlining a comprehensive evaluation framework, the publication aims to guide the development of treatments that mitigate severe neurological sequelae.
Important limitations
As a narrative review synthesizing existing literature, the analysis does not generate original experimental data or conduct primary clinical evaluations.
GIDS interpretation
This publication provides a conceptual framework for assessing antiviral candidates targeting a specific viral pathogen. Its focus on pharmacokinetic and neurological endpoints offers a structured reference point for researchers monitoring therapeutic development pipelines related to arboviral infections.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.